scholarly article | Q13442814 |
P2093 | author name string | Suzuki Y | |
Green MR | |||
Vogelzang NJ | |||
Corson JM | |||
Chahinian AP | |||
Herndon JE | |||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
patient | Q181600 | ||
P304 | page(s) | 723-731 | |
P577 | publication date | 1998-03-01 | |
P1433 | published in | Chest | Q5093377 |
P1476 | title | Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. | |
P478 | volume | 113 |
Q44649986 | A Multicenter Phase II Study of Gemcitabine and Oxaliplatin for Malignant Pleural Mesothelioma |
Q51643878 | A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index. |
Q33341861 | A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma |
Q34278435 | A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice |
Q38888134 | Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. |
Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
Q33813008 | An epigenetic mechanism for capecitabine resistance in mesothelioma |
Q36643416 | Angiogenesis is an independent prognostic factor in malignant mesothelioma |
Q36027639 | Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? |
Q51980244 | Automated matching of temporally sequential CT sections. |
Q38660038 | Biomarkers and prognostic factors for malignant pleural mesothelioma |
Q28387194 | Biomarkers and prognostic factors for mesothelioma |
Q37335377 | Biomarkers for malignant pleural mesothelioma: current status |
Q41086929 | Brain metastases in malignant pleural mesothelioma |
Q38119922 | Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. |
Q64235291 | Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP) |
Q44244488 | Characteristics of Malignant Pleural Mesothelioma in Women |
Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
Q36022779 | Chemotherapy options and new advances in malignant pleural mesothelioma |
Q52672893 | Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. |
Q53251663 | Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. |
Q36755228 | Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma |
Q50050310 | Clinical and biologic prognostic factors in malignant pleural mesothelioma |
Q36643797 | Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma |
Q86128168 | Clinical and pathological features are still the best determinants of prognosis in mesothelioma |
Q36723787 | Clinical significance of serum CA125 in diffuse malignant mesothelioma |
Q41522440 | Clinical staging of malignant pleural mesothelioma: current perspectives |
Q34239292 | Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma |
Q37029331 | Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma |
Q37086026 | Current concepts in malignant pleural mesothelioma. |
Q40568933 | Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells |
Q52685808 | Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. |
Q39434249 | Diagnosis and prognosis-review of biomarkers for mesothelioma. |
Q55463329 | Differential effects of tumor-platelet interaction in vitro and in vivo in glioblastoma. |
Q35578007 | Diffuse Malignant Pleural Mesothelioma: Part II. Symptom Management |
Q36702389 | Disease volumes as a marker for patient response in malignant pleural mesothelioma. |
Q36140968 | Distinctive clinical characteristics of malignant mesothelioma in young patients. |
Q36694116 | Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? |
Q36758593 | Emerging drugs for mesothelioma |
Q46548604 | Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma |
Q37214250 | Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma |
Q38437441 | Expression of bcl-2 family members in malignant pleural mesothelioma |
Q63413185 | Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. |
Q35678085 | Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales |
Q33914000 | Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma |
Q37449036 | Future developments in the management of malignant pleural mesothelioma |
Q31878746 | Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. |
Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
Q33339509 | High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. |
Q40804584 | High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. |
Q40684793 | Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma |
Q62392158 | Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma |
Q98735838 | Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients |
Q33877584 | Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. |
Q51613280 | Individualised management of malignant pleural effusion. |
Q39818881 | Individualizing Mesothelioma Treatment: Small Steps Into a Brighter Future |
Q37090789 | Inflammation in malignant mesothelioma - friend or foe? |
Q56976088 | Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53 |
Q74172131 | Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro |
Q44173242 | Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. |
Q35623638 | Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy. |
Q82051649 | Malignant Pleural Mesothelioma: A Population-Based Study of Survival |
Q52610273 | Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography? |
Q37261327 | Malignant mesothelioma after household exposure to asbestos |
Q47098675 | Malignant mesothelioma: Canadian perspective and research directions |
Q74267166 | Malignant pleural mesothelioma |
Q83412919 | Malignant pleural mesothelioma |
Q83466825 | Malignant pleural mesothelioma |
Q36766690 | Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review. |
Q35740408 | Malignant pleural mesothelioma--an update |
Q40041012 | Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data. |
Q33686248 | Malignant pleural mesothelioma: a single-center experience in Turkey |
Q55113818 | Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis. |
Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
Q33871571 | Malignant pleural mesothelioma: predictors and staging |
Q37277451 | Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
Q36830116 | Management options for malignant pleural mesothelioma: clinical and cost considerations |
Q38308730 | Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura |
Q51996240 | Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. |
Q37866663 | Medical treatment of mesothelioma: anything new? |
Q37201356 | Mesothelioma and asbestos-related pleural diseases |
Q35511541 | MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. |
Q42548512 | Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma |
Q29248127 | Modern management of malignant pleural mesothelioma |
Q36097706 | Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma |
Q36643866 | Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma |
Q43466291 | Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. |
Q35042668 | New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials |
Q36780582 | Newer issues in mesothelioma chemotherapy. |
Q36905239 | Optimising survival in malignant mesothelioma |
Q26825427 | Paraneoplastic thrombocytosis: the secrets of tumor self-promotion |
Q35782906 | Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma |
Q24243222 | Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma |
Q33379936 | Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. |
Q34678683 | Peritoneal mesothelioma |
Q39831596 | Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure |
Q39977787 | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma |
Q44874991 | Pleural mesothelioma: experience with 62 cases in 9 years |
Q36287976 | Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies |
Q34608340 | Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. |
Q35870489 | Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. |
Q28359542 | Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis |
Q54691246 | Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis. |
Q42373344 | Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. |
Q24679305 | Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems |
Q33918135 | Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey |
Q43875251 | Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma |
Q33390251 | Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas |
Q37426353 | Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma |
Q89759390 | Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma |
Q42000248 | Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma |
Q78192009 | Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma |
Q45020726 | Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. |
Q37090803 | Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? |
Q37307815 | Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma |
Q36425940 | Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma |
Q33227741 | Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase |
Q92591513 | Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy |
Q37290519 | Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. |
Q45740888 | Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma |
Q44080402 | Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis |
Q34041728 | Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. |
Q53733133 | Survival and Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Study of 314 patients in the West Part of Japan |
Q38607308 | Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response |
Q50286398 | Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors. |
Q93380858 | Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma |
Q51114246 | The clinicopathological characteristics with long-term outcomes in malignant mesothelioma. |
Q34558970 | The role of SV40 in malignant mesothelioma and other human malignancies |
Q33658554 | The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy |
Q47809790 | The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma |
Q43595658 | The value of inflammatory parameters in the prognosis of malignant mesothelioma |
Q53320850 | Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. |
Q37301691 | Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. |
Q44681845 | Treatment and survival analyses of malignant mesothelioma in Japan |
Q79267484 | Tumor Necrosis Correlates With Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma * |
Q26853099 | Tumor-platelet interaction in solid tumors |
Q36986796 | Unusual presentation and location pleural malignant mesothelioma |
Q38758684 | Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials |
Q36652941 | Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). |
Q39434239 | Volumetric assessment in malignant pleural mesothelioma |
Q37128016 | Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy? |
Q35172562 | Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma |
Q82061962 | [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] |
Q53893407 | [Malignant mesothelioma--a diagnostic challenge]. |
Q80352857 | [Malignant pleural mesothelioma: radiotherapy for the prevention of seeding nodules] |
Q38451233 | c-Kit is not expressed in malignant mesothelioma |
Q40466065 | miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. |
Search more.